
    
      Phase I dose ascending ("best of five") clinical trial.

      First group will start by intranodal injection in cervical lymph nodes of 5*10^6 tolDC-VitD3.

      Up titration depending on security outcomes to 10*10^6 tolDC-VitD3, same route in second
      cohort dose and next uptitration to 15*10^6 tolDC-VitD3.

      Six cycles per patient with the following schema: for the first four cycles the
      administration will be each 2 weeks, for the remaining 2 cycles administration each 4 weeks.

      A last cohort with the dose identified in the previous groups, administered in patients
      treated with beta interferon, same route, same dose schema.
    
  